Targeted Therapy: Anti-EGFR Treatment - PowerPoint PPT Presentation

targeted therapy anti egfr treatment n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Targeted Therapy: Anti-EGFR Treatment PowerPoint Presentation
Download Presentation
Targeted Therapy: Anti-EGFR Treatment

play fullscreen
1 / 16
Targeted Therapy: Anti-EGFR Treatment
229 Views
Download Presentation
baby
Download Presentation

Targeted Therapy: Anti-EGFR Treatment

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Targeted Therapy: Anti-EGFR Treatment January 27, 2006 Frankfurt am Main Germany

  2. Targeted Therapy: Anti-EGFR Treatment Moderator Jeffrey Myers M.D. Ph.D. Speaker Jan Vermorken M.D. Ph.D. Panelists Marshall Posner M.D. Wilfried Budach M.D. Jens Overgaard M.D.

  3. Targeted Therapy: Anti-EGFR Treatment Jan Vermorken M.D. Ph.D.

  4. Anti-EGFR treatment:Antibodies • What has been the experience with Anti-EGFR antibody therapy in the treatment of squamous cell carcinoma of the head and neck? • Using erbitux (C225, cetuximab)? • Using other antibodies? • What are the relative merits/shortcomings of C225 and other antibodies?

  5. Anti-EGFR treatment: Antibodies • What settings have these been studied in? What level of evidence exists for each? • Single agent • Refractory disease • Combination with chemotherapy • Refractory disease • Induction therapy • Adjuvant therapy - Combination with radiation therapy (will be discussed in a separate session devoted to this topic)

  6. Anti-EGFR treatment: Antibodies • What are the major mechanisms of action of anti-EGFR monoclonal antibodies that make them distinct from small molecule tyrosine kinase inhibitors?

  7. Anti-EGFR treatment: Antibodies • What are the major mechanisms of resistance to treatment with anti-EGFR monoclonal antibodies?

  8. Anti-EGFR treatment: Antibodies • Are there any molecular predictors (biomarkers) for sensitivity or resistance to treament with anti-EGFR monoclonal antibodies?

  9. Anti-EGFR treatment: Antibodies • Is skin rash a predictor for sensitivity or resistance to treament with anti-EGFR monoclonal antibodies?

  10. Anti-EGFR treatment: Antibodies • What is the experience with anti EGF-R antibodies in the treatment of tumors of the head and neck region other than Squamous Cell Carcinoma?

  11. Anti-EGFR treatment: Small molecule tyrosine kinase inhibitors (TKIs) • What has been the experience with Anti-EGFR TKIs in the treatment of squamous cell carcinoma of the head and neck? • Using gefitinib (Iressa)? • Using other inhibitors (erlotinib)? • What are the relative merits/shortcomings of gefitinib and other small molecules?

  12. Anti-EGFR treatment: TKIs • What settings have these been studied in? What level of evidence exists for each? • Single agent • Refractory disease • Combination with chemotherapy • Refractory disease • Induction therapy • Adjuvant therapy - Combination with radiation therapy (will be discussed in a separate session devoted to this topic)

  13. Anti-EGFR treatment: TKIs • What are the major mechanisms of resistance to treatment with anti-EGFR TKIs?

  14. Anti-EGFR treatment: TKIs • Are there any molecular predictors (biomarkers) for sensitivity or resistance to treament with anti-EGFR TKIs?

  15. Anti-EGFR treatment: TKIs • What is the experience with anti EGF-R TKIs in the treatment of tumors of the head and neck region other than Squamous Cell Carcinoma?

  16. Anti-EGFR treatment: Transcription Inhibitors • What has been the experience with Anti-EGFR transcriptional inhibitors for therapy in the treatment of squamous cell carcinoma of the head and neck or other tumor types?